Search for: "Schering Corporation, The"
Results 121 - 136
of 136
Sorted by Relevance
|
Sort by Date
12 Oct 2007, 7:03 am
Schering-Plough Corp., 2006 WL 2546494, at *2 (E.D. [read post]
16 Aug 2009, 11:23 am
., corporate buyers seeking to further their strategic objectives). [read post]
7 Jul 2010, 8:07 am
Schering-Plough Corp., 367 N.J. [read post]
23 Jul 2009, 3:15 am
Jan. 5, 2009); Novae Corporate Underwriting Ltd. v. [read post]
9 Nov 2010, 3:09 pm
Cancer Research Technology & Schering v. [read post]
30 May 2011, 4:55 am
Egg World, LLC (Seattle Trademark Lawyer) Parties choose ACR, TTAB finds SOLARIN not confusingly similar to SOLARCAINE for sun/tanning products: Schering-Plough HealthCare Products, Inc. v. [read post]
22 Oct 2009, 6:02 am
(Editor's Note: This post is based on a Gibson, Dunn & Crutcher LLP memorandum by Amy Goodman and Gillian McPhee.) [read post]
12 May 2015, 3:26 pm
., Inc. 902619386 UBS Yield Optimization Notes with Contingent Protection linked to General Electric Company 902619394 UBS Yield Optimization Notes with Contingent Protection linked to Exxon Mobil Corp. 902619493 UBS Yield Optimization Notes with Contingent Protection linked to Texas Instruments Inc 902619519 UBS Yield Optimization Notes with Contingent Protection linked to Amgen Inc. 902619527 UBS Yield Optimization Notes with Contingent Protection linked to Goldcorp Inc. 902619535 UBS Yield… [read post]
23 Feb 2010, 6:16 am
Editor’s Note: John Olson is a founding partner of Gibson, Dunn & Crutcher’s Washington, D.C. office and a visiting professor at the Georgetown Law Center. [read post]
13 Jun 2008, 3:40 am
, Schering-Plough Corp – Following dispute over trade dress with Schering-Plough, Fruit of the Earth announces plan to change its package design: (IP Law360), US: Quanta and its impact on biotechnology: (Holman’s Biotech IP Blog), US: BIO files amicus brief asking CAFC to cabin in scope of KSR and hold that its obvious to try dicta does not abrogate the Deuel standard: In re Kubin: (Patently-O), US: StemCells gets patent on enriched central nervous system stem… [read post]
28 Apr 2008, 11:00 am
: (Patent Docs), US: Supreme Court declines to hear final Nucleonics’ appeal in gene-silencing patent dispute with Benitec Australia: (IP Law360), (Therapeutics Daily), US: 505(b)(2) drug approvals rock - Interaction of patents and exclusivity of drugs approved by FDA under section 505(b)(2): (Patent Baristas), US: StemCells’ patents survive reexam – StemCells and Neuralstem differ on extent of changes: (Patent Docs), US: StemCells announces issuance of… [read post]
15 Feb 2008, 9:00 am
: (Spicy IP),USD 20 billion going off-patent: (Patent Circle),Canadian Prices Review Board asserts jurisdiction over products sold in US, but imported into Canada under Special Access Program: (Gowlings),Canadian Court of Appeal affirms decision allowing patent-owner to be joined to proceedings: Cobalt v Pfizer and Pharmascience v Pfizer: (Gowlings),PharmaStem appeals stem cell patent: asks for greater deference to patent examiners: PharmaStem … [read post]
15 Mar 2008, 7:00 am
Shame about the IP: (Afro-IP),Ethiopia receives US trade mark for Sidamo coffee despite opposition from Starbucks: (The IP Factor), (Afro-IP),CC licensed test for African sleeping sickness: (creativecommons.org),Update on PCT applications filed in Nigeria: (Afro-IP),Parallel imports of DVDs to be tested in South Africa: Universal City Studios v Mr Video: (Afro-IP),The W****D C*P of 2*1*: FIFA’s intellectual property rights in South Africa: (Afro-IP),Namibia to adopt competition… [read post]
3 Apr 2009, 7:23 pm
Here is IP Think Tank’s weekly selection of top intellectual property news breaking in the blogosphere and internet. [read post]
7 Mar 2008, 2:00 am
: (IPBiz), US: Proposals for the approval of generic biologics under consideration: (Pharmacapsules@Gowlings), US: A paradigm shift in obviousness for pharma, biotech: (IP Law360), US: USPTO’s Bruce Kisliuk addresses ACI Pharma/biotech patent claim drafting and prosecution conference: (Patent Docs), US: New bill to provide biotech companies Sarbanes-Oxley relief: (California Biotech Law Blog), US: Biotech and pharma companies spent millions on lobbying in 2007: (Patent… [read post]
17 Jun 2010, 6:47 am
In its brief, the DOL argues that the district court in that case committed legal error when it concluded that the pharmaceutical sales representatives employed by Novartis Pharmaceutical Corporation (“NPC”) were exempt from the overtime requirements of the FLSA under the outsides sales and administrative exemptions. [read post]
